U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
The blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback